Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Beyond the trial: Real-world CRS, icans, and healthcare burden of CAR T-cell therapy across US oncology practices

View Full Paper
Ask AI
Bookmark
Share

Authors

LCLi ChenNWNiquelle Brown WadéSRSelina Radlein

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows higher healthcare resource utilization for CAR T toxicity management in DLBCL and MCL.

Key Points

  • To assess the prevalence and treatment of cytokine release syndrome and ICANS, and their healthcare costs in CAR T patients.
  • Retrospective cohort study using Flatiron Health Research Database
  • Included patients treated with CAR T for DLBCL, MCL, and MM
  • Evaluated toxicity management and healthcare resource utilization
  • Characterized adverse events by grade, treatment, and setting
  • 66% of DLBCL, 76% of MCL, and 77% of MM patients experienced any grade cytokine release syndrome
  • 51% hospitalization rate after CAR T for DLBCL, 69% for MCL, and 56% for MM
  • CRS and ICANS resolution rates varied between 70%-85% depending on disease
  • Significant decrease in grade >3 CRS events over time in DLBCL

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236debfhttps://doi.org/10.1182/blood-2025-6263
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Burden and outcomes of CAR T-cell therapy toxicities in DLBCL, multiple myeloma, and B-ALL: A nationwide analysis2025
  2. 2Early intervention for cytokine release syndrome after chimeric antigen receptor T-cell therapy is associated with an increased risk of cytopenias and infections in patients with large B-cell lymphoma2025
  3. 3National burden and outcomes of CAR-T therapy toxicities in DLBCL, multiple myeloma, and B-ALL: A retrospective analysis of the Nationwide Inpatient Sample.2026
  4. 4Barriers and bridges: Real-world CAR T delivery across US oncology practices2025 · 2 citations
  5. 5Inpatient CAR-T safety in the United States: Severe ICANS and CRS by donor source and antigen target (NIS 2022–2023).2026